appliedclinicaltrialsonline2d
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...
appliedclinicaltrialsonline3d
2025 Trends: Leveraging Data Standards
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, highlights how data standards are empowering the use of ...
appliedclinicaltrialsonline3d
FDA Approves Eli Lilly’s Omvoh for Crohn’s Disease Based on Phase III VIVID-1 Trial Outcomes
In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...
appliedclinicaltrialsonline3d
Long-Term KATHERINE Trial Analysis Shows Kadcyla Significantly Improves Survival in HER2-Positive Early Breast Cancer
An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...
appliedclinicaltrialsonline4d
2025 Trends: Advancements in Data Interoperability
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, talks protocol submission formats and how data interoperability can support artificial intelligence.
appliedclinicaltrialsonline4d
Five Predictions That Will Drive R&D Effectiveness in 2025
In 2025, sponsors will prioritize contract research organizations (CROs) offering complete and continuous data transparency ...
appliedclinicaltrialsonline4d
Streamlining Protocol Development Timelines
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, discusses historical challenges with long protocol ...